InVivo Therapeutics lowers net loss, realizes $11.8M cost savings in 2018: 4 key notes

InVivo Therapeutics reported raising net proceeds of $16.5 million in 2018 and implemented significant cost savings measures last year.

Advertisement

Four things to know:

1. The company reported operating expenses at $12.7 million, down 48 percent from $24.6 million in 2017.

2. InVivo reported a $23.4 million net loss for 2018, down from $26.7 million in the previous year.

3. The company focused on initiating the Inspire 2.0 Study last year with five clinical sites that are now open for enrollment. The company aims to begin enrollment in the second quarter of 2019.

4. InVivo reported its cost saving measures decreased operating expenses 48 percent year over year, which hit $11.8 million last year.

More articles on spine devices:
What drives orthopedic, spine device company M&A and what to watch through 2020
Stryker makes 2 legal leadership changes
Have some PODs violatd the Sunshine Act reporting requirements?

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Biologics

Advertisement

Comments are closed.